MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.adro.2021.100888

Медицинская библиотека · Advances in radiation oncology · 2021

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials.

Prasad Rahul N, McIntyre Mark, Guha Avirup, Carter Rebecca R, Yildiz Vedat O, Paskett Electra, Lustberg Maryam, Ruz Patrick, Williams Terence M, Kola-Kehinde Onaopepo, Miller Eric D, Addison Daniel

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in cancer survivors, particularly after chest radiation therapy (RT). However, the extent to which CVD events are consistently reported in contemporary prospective trials is unknown.

METHODS AND MATERIALS: From 10 high-impact RT, oncology, and medicine journals, we identified all latter phase trials from 2000 to 2019 enrolling patients with breast, lung, lymphoma, mesothelioma, or esophageal cancer wherein chest-RT was delivered. The primary outcome was the report of major adverse cardiac events (MACEs), defined as incident myocardial infarction, heart failure, coronary revascularization, arrhythmia, stroke, or CVD death across treatment arms. The secondary outcome was the report of any CVD event. Multivariable regression was used to identify factors associated with CVD reporting. Pooled annualized incidence rates of MACEs across RT trials were compared with contemporary population rates using relative risks (RRs).

RESULTS

The 108 trials that met criteria enrolled 59,070 patients (mean age, 58.0 ± 10.2 years; 46.0% female), with 273,587 person-years of available follow-up. During a median follow-up of 48 months, 468 MACEs were reported (including 96 heart failures, 75 acute coronary syndrome, 1 revascularization, 94 arrhythmias, 28 strokes, and 20 CVD deaths; 307 occurred in the intervention arms vs 144 in the control arms; RR, 1.96; P < .001). Altogether, 50.0% of trials did not report MACEs, and 37.0% did not report any CVD. The overall weighted-trial incidence was 376 events per 100,000 person-years compared with 1408 events per 100,000 person-years in similar nontrial patients (RR, 0.27; P < .001). There were no RT factors associated with CVD reporting.

CONCLUSION

In contemporary chest RT-based clinical trials, reported CVD rates were lower than expected population rates.

Для цитирования: Prasad Rahul N, McIntyre Mark, Guha Avirup, Carter Rebecca R, Yildiz Vedat O, Paskett Electra, Lustberg Maryam, Ruz Patrick, Williams Terence M, Kola-Kehinde Onaopepo, Miller Eric D, Addison Daniel. Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials.. Advances in radiation oncology. 2021. DOI: 10.1016/j.adro.2021.100888.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.